Co-Diagnostics Inc. (CODX)

AI Score

Unlock

0.32

-0.07 (-18.26%)

At close: Mar 28, 2025, 3:59 PM

0.33

2.75%

After-hours: Mar 28, 2025, 06:17 PM EDT

-18.26% (1D)

Bid	0.28
Market Cap	10.22M
Revenue (ttm)	4.83M
Net Income (ttm)	-43.23M
EPS (ttm)	-1.38
PE Ratio (ttm)	-0.23
Forward PE	-0.67
Analyst	Hold

Ask	0.41
Volume	818,027
Avg. Volume (20D)	236,093
Open	0.38
Previous Close	0.39
Day's Range	0.28 - 0.38
52-Week Range	0.28 - 2.23
Beta	1.30

About CODX

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to ...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Jul 12, 2017

Employees 155

Stock Exchange NASDAQ

Ticker Symbol CODX

Website https://www.codiagnostics.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for CODX stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 212.50% from the latest price.

Stock Forecasts

Earnings Surprise

Co-Diagnostics has released their quartely earnings on Mar 27, 2025:

Revenue of $149.32K misses estimates by $225.68K, with -95.80% YoY decline.

EPS of -0.36 misses estimates by -0.02, with 28.00% YoY growth.

Next Earnings Release

Co-Diagnostics Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

+7.2%

Co-Diagnostics shares are trading higher after the... Unlock content with Pro Subscription

7 months ago

+12.9%

Co-Diagnostics shares are trading higher after the CDC announced free at home Covid 19 test delivery programs will reopen in late September.

News

1 day ago · zacks.com

Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.

1 day ago · seekingalpha.com

Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants ...

1 month ago · benzinga.com

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

On Friday, Co-Diagnostics, Inc. CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance.